Kevin O'Connor, PhD

Associate Professor of Neurology

Research Departments & Organizations

Neurology: Nowak Lab | O'Connor Lab

Immunobiology: Human and Translational Immunology Program

IBM Registry

Office of Cooperative Research

Research Interests

Immune System Diseases; Multiple Sclerosis; Musculoskeletal Diseases; Myasthenia Gravis; Nervous System Diseases; Neurology

Research Summary

The O’Connor laboratory, is part of the Department of Neurology and program in Human Translational Immunology (HTI) at Yale University School of Medicine. The aim of our research is to further elucidate the role that B cells play in disease. We are specifically interested in defining the mechanisms by which B cells, and the antibodies they produce, affect tissue damage in autoimmunity and participate in tumor biology. To this end we are engaged in determining the specificity of autoantibodies and understanding the mechanisms by which B cells organize in autoimmune tissue. Areas of special interest in our autoimmunity program include multiple sclerosis, inflammatory myopathy and myasthenia gravis. Our cancer program is currently focused on meningiomas and germ cell tumors.

Extensive Research Description

Multiple sclerosis. B-cell depletion therapy in MS results in a remarkable reduction in new inflammatory brain lesions and clinical relapses, indicating that B cells contribute to MS pathology. How they do so is not well understood. We have built a program that is focused on furthering the understanding of the role that B cells and antibodies play in the pathology of MS. To this end, my group is investigating the following fundamental questions in MS: What are the antigen targets of MS B cells? Through the application of novel technologies, we demonstrated that autoantibodies to the encephalogenic myelin antigens, MBP and MOG are uncommon in the serum and CSF of adult patients with MS [1-4]. This turned our interest toward the B cells that accumulate at the site of tissue injury, the MS CNS. Here, we are elucidating the antigen specificity of B cells that reside within MS lesions. Our strategy harnesses the adaptive response of the humoral immune system by using the machinery of the B cells present in these tissues to isolate autoantigens [5]. Laser capture micro-dissection is used to isolate single B cells directly from CNS tissue. Single-cell PCR then amplifies the antibody variable regions, sequencing of which provides information concerning expanded clones and evidence of those that have experienced antigen-driven stimulation. Then, large amounts of recombinant, whole IgG from selected clones are produced. The IgG is then used to capture antigens from candidate sources. The precise molecular definition of isolated antigen(s) is then determined through sophisticated mass spectrometric methodologies. To date, we have isolated and identified a number of candidate autoantigens, validation of which is under way. What is the relationship between the antibodies and the B cells present in the CSF and CNS tissue and to those in the periphery? While B cells and antibodies are present in the CSF and CNS tissue of patients with MS, the relationship among them is not understood. We have constructed immunoglobulin transcriptomes and proteomes from CNS tissue and CSF that allowed us to determine that these compartmentalized B cells and antibodies are clonally related [6, 7]. We have now turned our attention toward determining how these cells are related to the peripheral B cell repertoire. We are currently using high-throughput sequencing to build immunoglobulin transcriptomes from the cervical lymph nodes, which will be compared to those derived from CNS lesions and the CSF. How do MS CNS B cells function as antigen-presenting cells? We are developing a model system engineered to examine the role of human MS CNS-derived immunoglobulin in the pathogenic progression of CNS demyelination. Specifically, we will build a mouse model genetically engineered to develop B cells expressing immunoglobulin derived from pervasive human MS CNS clones. This model will allow the study of the contribution that MS CNS-derived immunoglobulin and B cells make to CNS demyelination and tissue injury

Myasthenia gravis. Autoreactive B-cells are thought to play an important role in the immunopathogenesis of MG. Early studies, including one at Yale, indicate that B cell depletion therapy is beneficial to MG patients [8]. It is unclear what specific changes in the immune system are associated with the observed clinical improvement. Accordingly, the rationale for this work is to further understand rituximab’s mechanism of action by measuring its effects on immunity in MG. Molecular and cellular immune system components, which putatively participate in the pathology of MG, will be measured at points prior to, during and after rituximab-mediated B cell depletion. We are developing/adapting immunoassays so that we can measure: Autoantibody titer of MuSK and AChR; Antigen specific B cells and plasma cells; Repertoire and characteristics of antigen specific B cells; Antigen specific T-helper cells; Cytokine profiles of antigen specific T cells. We expect to identify changes in the immune system of MG patients undergoing treatment and these data will be related to measurements of clinical outcome. This work represents a first step toward gaining a more complete understanding of the immune mechanisms underlying treatment of MG with rituximab and will lead to new ways to prevent or treat the disease.

The inflammatory myopathies are a group of autoimmune diseases characterized by progressive skeletal muscle weakness associated with inflammatory cell infiltration within the muscle. The muscle mRNA from a subset of IM patients harbors an abundance of Ig transcripts. Although sparse numbers of CD19 or CD20 B cells are present in IM muscle tissue, we reported that large numbers of CD138 plasma cells are present and that these cells are the source of the Ig transcripts. These findings led us to hypothesize that we would find evidence of an Ag-driven immune response in the tissue of patients with particular IMs. Through investigating the B cell and plasma cell Ig repertoire in muscle biopsies we confirmed that such an antigen-driven response was occurring in this autoimmune tissue [9]. We then set out to identify the antigen driving this response using recombinant IgG derived from plasma cells harbored in the muscle tissue. We are currently evaluating the validity of a novel muscle-associated autoantigen isolated using this strategy.

Our cancer program is currently focused on meningiomas and germ cell tumors. These tumors invariably harbor an immune cell infiltrate comprised, in part, of B cells, yet little is known of their role. We are using novel strategies to understand further the characteristics of the B cells commonly found within these tumors. A variety of procedures for the isolation of tumor antigens exist, yet the identification of real and reliable tumor-specific structures is difficult. Thus, our goal is to identify tumor-specific antigen(s) by harnessing the adaptive response of the humoral immune system present in the tumor microenvironment. Such molecular tools represent a sophisticated and reliable strategy both to investigate tumor-associated antibody specificity and to discover novel, tumor-associated antigens that can be used as potential targets in tumor diagnostics or therapeutics. Our work has focused on germ cell tumors, a principal feature of which is that they invariably harbor a prominent immune cell infiltrate. Data collected by our group indicate that germ cell tumors drive tumor-associated B cells toward antibody production that targets specific tumor antigens [10]. To isolate these antigens we have adapted the strategy used in our MS antigen discovery program (described above). The identification of tumor-specific antigens represents a fundamental step toward understanding the biology and the role of the immune system in this tumor family. Moreover, novel tumor antigens may lead to the development of targeted immunotherapy that may be highly efficacious and better tolerated than current treatment strategies.

Multiple sclerosis

Myasthenia gravis

Tumor immunology

Inflammatory myopathies

Clinical Trials

Conditions Study Title
Diseases of the Nervous System Immunologic Mechanisms in Neurological Diseases
Diseases of the Nervous System Phase II Trial of Rituximab In Myasthenia Gravis

Selected Publications

See list of PubMed publications

Edit this profile